Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;45(11):1599-1607.
doi: 10.1007/s00270-022-03072-8. Epub 2022 Feb 11.

TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC

Boris Guiu #  1 , Etienne Garin #  2 , Carole Allimant  3 , Julien Edeline  4 , Riad Salem  5
Affiliations
Review

TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC

Boris Guiu et al. Cardiovasc Intervent Radiol. 2022 Nov.

Abstract

The Barcelona Clinic Liver Cancer (BCLC) system is the most commonly used staging system for hepatocellular carcinoma (HCC) in Western countries. BCLC aims to categorize patients into five stages with different prognoses and to allocate treatment according to these stages based on the best possible contemporary evidence. Transarterial radioembolization (TARE) has recently entered at the left of the BCLC algorithm (i.e., BCLC 0-A), mainly because of negative phase III trials in BCLC C stage. TARE has shown a steady increase in nationwide studies over the past 20 years and has even been adopted in some tertiary centers as the primary HCC treatment across all BCLC stages. We aimed to review the history of TARE in HCC, starting from advanced HCC and gradually expanding to earlier stages at the left of the BCLC system.

Keywords: Dosimetry; Liver cancer; Radioembolization; Yttrium.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Golfieri R, Bargellini I, Spreafico C, Trevisani F. Patients with Barcelona clinic liver cancer stages B and C hepatocellular carcinoma: time for a subclassification. Liver Cancer. 2019;8(2):78–91. - PubMed
    1. EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
    1. Matsumoto MM, Mouli S, Saxena P, Gabr A, Riaz A, Kulik L, et al. Comparing real world, personalized, multidisciplinary tumor board recommendations with bclc algorithm: 321-patient analysis. Cardiovasc Intervent Radiol. 2021;44(7):1070–80. - PubMed
    1. Salem R, Gabr A, Riaz A, Mora R, Ali R, Abecassis M, et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1000-patient 15-year experience. Hepatology. 2018;68(4):1429–40. - PubMed
    1. Reig M, Forner A, Rimola J, Ferrer-Fábrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation Barcelona clinic liver cancer (BCLC) staging system. The 2022 update. J Hepatol 2021.

Substances

LinkOut - more resources

-